GoAI
Get started
Taiko Pharmaceutical Co.,Ltd. logo

Taiko Pharmaceutical Co.,Ltd.

4574.T

JPXHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

¥269

+¥1.00 · +0.37%

Aug 24, 2:38 PM JST

4574.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Taiko Pharmaceutical Co.,Ltd. operates primarily in the pharmaceutical sector and the field of infection prevention. The company manufactures and distributes various over-the-counter medications, including its well-known Seirogan and Seirogan Toi-A brands, which are formulated to alleviate symptoms such as loose stools, diarrhea, vomiting, and ailments stemming from food or water contamination. Additionally, it provides specific tablets for diarrhea relief and quasi-pharmaceuticals like the Trumpet Intestinal Regulator BF. In its infection control segment, Taiko Pharmaceutical produces and supplies a range of sanitation products under the Cleverin brand to wholesalers. This includes the Cleverin generator, a device engineered to emit low concentrations of chlorine dioxide gas. The company also leverages its proprietary Cleverin technology by supplying it through original equipment manufacturer (OEM) agreements and engaging in joint product development ventures with other businesses. Its products are exported to several countries, including the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was founded in 1946 and is headquartered in Osaka, Japan.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
JP
CEO
Takashi Shibata
Listed since
Mar 18, 2009
Employees
220

Market position

Day range

Current ¥269

52-week range

Current ¥269

Open
¥268
Previous close
¥268
Volume
65.6K
0.6× average
Average volume
110.01K
Average daily volume
Market cap
13.52B JPY
Beta
0.05
Market reference 1
50-day average
¥264.54
+1.69% above average
200-day average
¥283.7
-5.18% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
19.65×
P/B (TTM)
1.6×
P/S (TTM)
2.04×
Dividend yield
1.23%

Profitability & efficiency

Gross margin
52.85%
Operating margin
6.48%
Net margin
10.39%

Financial health

Debt / equity
0.02×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends74%12%-50%-113%Gross margin, FY2021: 25.62%Gross margin, FY2022: 21.41%Gross margin, FY2023: 42.11%Gross margin, FY2024: 58.26%Gross margin, FY2025: 54.42%Operating margin, FY2021: -46.16%Operating margin, FY2022: -61.09%Operating margin, FY2023: -16.42%Operating margin, FY2024: 10.00%Operating margin, FY2025: 7.18%Net margin, FY2021: -89.49%Net margin, FY2022: -97.10%Net margin, FY2023: -59.00%Net margin, FY2024: 14.27%Net margin, FY2025: 14.43%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 25.62%. Gross margin FY2022 21.41%. Gross margin FY2023 42.11%. Gross margin FY2024 58.26%. Gross margin FY2025 54.42%. Operating margin FY2021 -46.16%. Operating margin FY2022 -61.09%. Operating margin FY2023 -16.42%. Operating margin FY2024 10.00%. Operating margin FY2025 7.18%. Net margin FY2021 -89.49%. Net margin FY2022 -97.10%. Net margin FY2023 -59.00%. Net margin FY2024 14.27%. Net margin FY2025 14.43%.

Income trends

Revenue

6.4B JPY+1.67%

Operating income

459M JPY-27.03%

Net income

923M JPY+2.78%
Income trends across reported periods12.75B JPY4.63B JPY−3.5B JPY−11.62B JPYRevenue, FY2021: 10.72B JPYRevenue, FY2022: 5.04B JPYRevenue, FY2023: 6.12B JPYRevenue, FY2024: 6.29B JPYRevenue, FY2025: 6.4B JPYOperating income, FY2021: −4.95B JPYOperating income, FY2022: −3.08B JPYOperating income, FY2023: −1.01B JPYOperating income, FY2024: 629M JPYOperating income, FY2025: 459M JPYNet income, FY2021: −9.59B JPYNet income, FY2022: −4.89B JPYNet income, FY2023: −3.61B JPYNet income, FY2024: 898M JPYNet income, FY2025: 923M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 10.72B JPY. Revenue FY2022 5.04B JPY. Revenue FY2023 6.12B JPY. Revenue FY2024 6.29B JPY. Revenue FY2025 6.4B JPY. Operating income FY2021 −4.95B JPY. Operating income FY2022 −3.08B JPY. Operating income FY2023 −1.01B JPY. Operating income FY2024 629M JPY. Operating income FY2025 459M JPY. Net income FY2021 −9.59B JPY. Net income FY2022 −4.89B JPY. Net income FY2023 −3.61B JPY. Net income FY2024 898M JPY. Net income FY2025 923M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue6.4B JPY6.29B JPY6.12B JPY5.04B JPY10.72B JPY
Cost of goods sold2.92B JPY2.63B JPY3.54B JPY3.96B JPY7.97B JPY
Gross profit3.48B JPY3.67B JPY2.58B JPY1.08B JPY2.75B JPY
Research and development—183M JPY245M JPY——
Selling, general, and administrative3.02B JPY2.85B JPY3.58B JPY——
Operating expenses3.02B JPY3.04B JPY3.58B JPY4.16B JPY7.69B JPY
Interest income16M JPY30M JPY25M JPY5M JPY3M JPY
Interest expense5M JPY8M JPY8M JPY10M JPY6M JPY
Depreciation and amortization265M JPY256M JPY704M JPY737M JPY941M JPY
Operating income459M JPY629M JPY−1.01B JPY−3.08B JPY−4.95B JPY
Net income923M JPY898M JPY−3.61B JPY−4.89B JPY−9.59B JPY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
18.37
FY2025 · +2.68% year over year
Latest fiscal-year revenue
6.4B JPY
FY2025 · +1.67% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend42.26-53.28-148.83-244.36FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend11.29B9.02B6.74B4.47BFY21FY22FY23FY24FY25

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

¥3.30

2025 complete year-50.5% since 2018

Corporate action history

DividendUpcoming

Ex-dividend Dec 29, 2026

¥3.50

Annual

Record Dec 31, 2026 · Payment Dec 29, 2026

Dividend

Ex-dividend Dec 29, 2025

¥3.30

Annual

Record Dec 31, 2025 · Payment Mar 30, 2026

Dividend

Ex-dividend Dec 29, 2021

¥13.00

Semi-Annual

Record Dec 31, 2021

Dividend

Ex-dividend Jun 29, 2021

¥7.00

Irregular

Record Jun 30, 2021

Dividend

Ex-dividend Dec 29, 2020

¥18.00

Special

Record Dec 31, 2020 · Payment Mar 31, 2021

Dividend

Ex-dividend Sep 29, 2020

¥7.00

Annual

Record Sep 30, 2020 · Payment Dec 14, 2020

4574.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,989

-0.31%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,817

+0.92%

HOYA Corporation logo

7741.T

HOYA Corporation

¥25,030

+0.54%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,280

+0.70%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,866.5

+1.16%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,405

+0.75%

ETFs holding 4574.T

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core TOPIX ETF logoiShares Core TOPIX ETF1475.T
Market value
24.63M
Weight
0.00%
AUM
2.89T JPY
Expense ratio
0.05%
Price / 1D
¥418.7+0.17%

Continue in GoAI

Research 4574.T

research.disclaimer